The second human vaccinee serum set was from humans subjects vaccinated with a new CGMP formulation of LVS (DVC lot 17) and was obtained from a Phase I clinical trial carried out at the Baylor College of Medicine, Houston, TX.
The study design and administration of the vaccine was described in detail previously (El Sahly et al., 2009), with dosages of 103, 105, 107 and 109 CFU/mL administered by scarification.
Five sets of sera (paired pre- and 42 days post-vaccination) and three unpaired sera (post-vaccination) were provided (Table 1). Representative Western blots probed using sera from vaccinees receiving LVS lot 17 are shown in Fig. 1 g and h, with the total set of blots shown in Fig. S4.